0
0

Cart (0)

Home > Categories > Lapatinib

Lapatinib

Sort by
Wishlist

Lapatinib nitroso impurity

  • CAT NUMBER DCTI-C-2588
  • CAS NUMBER NA
  • MOLECULAR FORMULA C29H25ClFN5O5S
  • MOLECULAR WEIGHT 610.06
Wishlist
Wishlist

LAPATINIB SELATINIB IMPURITY

  • CAT NUMBER DCTI-C-3047
  • CAS NUMBER 1275595-86-2
  • MOLECULAR FORMULA C29H26ClFN4O3S
  • MOLECULAR WEIGHT 565.06
Wishlist
LOAD MORE
You're viewed all 11 products
References
FAQ's

References

  1. Carter, Malcolm Clive; Cockerill, George Stuart; Guntrip, Stephen Barry; Lackey, Karen Elizabeth; Smith, Kathryn Jane, Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, Glaxo Group Limited, United Kingdom, EP1047694B1, July 7, 2004  
  1. Bai, Feng; Freeman, Burgess B.; Fraga, Charles H.; Fouladi, Maryam; Stewart, Clinton F., Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS), Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 831, Issue: 1-2 Pages: 169-175, 2006

Frequently Asked Questions

Yes, formulation adjustments can minimize impurities in Lapatinib, such as optimizing the pH, solvent selection, or using stabilizing agents.

Lapatinib impurities are controlled during manufacturing through strict quality control measures, such as process optimization, purification techniques, and adherence to good manufacturing practices (GMP).

Lapatinib impurities are analyzed using various analytical techniques, such as high-performance liquid chromatography (HPLC) or liquid chromatography (LC).

The recommendation is to store Lapatinib impurities at controlled room temperature, within 2-8 °C.

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart